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Abstract
Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings
regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has
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Bayer AG low incidence of severe toxicities and no black box warnings, but chronic treatment
effects were unknown. We provide an update on safety and efficacy of copanlisib with a
minimum 2-year follow-up of the CHRONOS-1 study. A total of 142 patients with
histologically confirmed indolent B-cell lymphoma who had relapsed after or were refrac-
tory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and
15 (28-day cycle). The primary efficacy endpoint was objective response rate (ORR) after
≥4 cycles (independent assessment). The predominant histology was follicular lymphoma
(n = 104). The ORR was 60.6% (seven additional complete responses since primary anal-
ysis). Secondary endpoints of median duration of response, progression-free survival, and
overall survival were 14.1 months (median follow-up, 16.1 months), 12.5 months (median
follow-up, 14.0 months), and 42.6 months (median follow-up, 31.5 months), respectively.
Median safety follow-up was 6.7 months; 26% of patients received treatment for >1 year.
Common treatment-emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were
transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient
hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs
were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or
grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening
following longer exposure in patients treated >1 year. Long-term follow-up of patients
with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib
demonstrated durable, enhanced responses without evidence of worsening TEAEs, as
reported for orally administered PI3K inhibitors.
1 | INTRODUCTION
Indolent B-cell lymphomas are often incurable due to frequent relapse
following an initial response to first-line therapy and eventual devel-
opment of refractory disease, representing a significant challenge for
treatment and a high unmet need.1 Several phosphatidylinositol
3-kinase (PI3K) inhibitors are either approved or in development to
target the aberrant PI3K signaling that underlies tumor progression in
several types of cancer, including lymphoma.2-7 Clinical benefit has
been reported in patients with indolent lymphoma2,5,6; however, data
on the long-term effectiveness of PI3K inhibitors remain limited. In
addition, several orally administered agents targeting the PI3K path-
way have demonstrated adverse events (AEs), such as autoimmune
dysfunction and opportunistic infections,8 with reports of more
severe late-onset toxicities such as diarrhea and ulcerative colitis.9,10
Such PI3K-associated toxicities have caused the US Food and Drug
Administration (FDA) to include warning statements as part of the
prescribing information for orally administered PI3K inhibitors.11,12
Hence, there is an unmet need for long-term treatment options that
are both safe and effective in this patient population with advanced
and difficult-to-treat lymphoma.
Copanlisib (Bayer AG, Berlin, Germany) is an intravenous pan-
class I PI3K inhibitor with predominant and potent activity against the
PI3K-α and PI3K-δ isoforms.13,14 Copanlisib is indicated in the US for
the treatment of patients with relapsed follicular lymphoma (FL) who
have received at least two prior systemic therapies.15 Clinically
significant activity was demonstrated in a population of patients with
relapsed or refractory indolent B-cell lymphoma who had received at
least two prior therapies in a large phase 2, multicenter, open-label
study (CHRONOS-1; NCT01660451, Part B). The primary efficacy
endpoint of that study was objective response rate (ORR); 84 of
142 patients achieved an objective response, giving an ORR of
59.2%.2 At the time of the primary analysis, the minimum follow-up
from the date of the last patient initiating treatment was only
4 months, with an overall median duration of safety follow-up of
24 weeks. There were low rates of severe hepatic transaminitis, diar-
rhea, pneumonitis, and colitis (0.7%) and infrequent opportunistic
infections, fatal infections, or other fatal AEs.2 Based largely on these
results, copanlisib was approved by the US FDA without the so-called
black box warning.
To gain a better understanding of the safety and efficacy associ-
ated with long-term use of an intravenous PI3K inhibitor, including
patients treated for 1 year or more, we report here the safety and effi-
cacy from a 2-year follow-up of patients treated with copanlisib in the
CHRONOS-1 study.
2 | METHODS
Detailed methods of the CHRONOS-1 study have been reported previ-
ously.2 Briefly, this was an open-label, single-arm, phase 2 study evalu-
ating the efficacy and safety of single-agent copanlisib in patients with
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histologically confirmed indolent B-cell lymphoma who had relapsed
after or were refractory to at least two prior lines of treatment
(clinicaltrials.gov; NCT01660451, Part B). Eligibility criteria included
patients aged ≥18 years with histologically confirmed indolent B-cell
lymphoma, including FL grades 1 to 3a, marginal zone lymphoma (MZL),
small lymphocytic lymphoma (SLL), and Waldenström macroglobuline-
mia/lymphoplasmacytoid lymphoma (WM/LPL), who had previously
received rituximab and an alkylating agent or regimen. Patients were
also required to have at least one bidimensionally measurable lesion16
and an Eastern Cooperative Oncology Group performance status
(ECOG PS) of ≥2.
Copanlisib was administered at a fixed dose of 60 mg via a
1-hour intravenous infusion on an intermittent schedule, on days 1, 8,
and 15 of a 28-day cycle until progression or unacceptable toxicity.
The primary efficacy variable was ORR after 4 or more cycles
of treatment, defined as the proportion of patients who had a
best response rating of complete response or partial response
according to central radiologic review. Secondary efficacy vari-
ables included duration of response (DoR), progression-free sur-
vival (PFS), overall survival (OS), best change in target lesions, and
disease control rate.
Tumors were assessed by computed tomography scan or mag-
netic resonance imaging at screening and every 2 cycles during year
1, every 3 cycles during year 2, and every 6 cycles during year
3. Response was determined by independent radiologic review.16 For
patients with WM, very good partial response and minor response
categories were omitted from the response categories published by
the Sixth International Workshop on Waldenström's Macroglobuline-
mia.17 A safety follow-up visit was scheduled to occur within 30 to
35 days after the last study treatment, followed by scheduled visits
every 3 months. The AEs were reported per the Medical Dictionary
for Regulatory Activities version 20.1, and graded per the National
Cancer Institute Common Terminology Criteria for Adverse Events
version 4.03. Prophylaxis for opportunistic infection was not
mandated.
All patients who received treatment comprised the full analy-
sis set and were included in analyses, unless otherwise specified.
Prespecified evaluation of the primary efficacy variable was per-
formed using a one-sided exact binomial test (α = 2.5%), rejecting
the null hypothesis of an ORR of ≤40%. Estimates were calcu-
lated, and exact 95% confidence intervals (CI) were determined
using the Clopper–Pearson method. Kaplan–Meier estimates were
used to describe time-to-event variables. Median follow-up of
efficacy variables was calculated using the method of Schemper
et al.18 Statistical evaluations were completed using Statistical
Analysis System 9.2 software or higher (SAS Institute, Cary, NC,
USA) and R version 3.2.3/3.3.0 (The R Foundation, Vienna,
Austria).
Each patient provided written, informed consent. Study method-
ologies conformed to the standards set by the Declaration of Helsinki
and were approved by the appropriate ethics committee at each study
site. All authors had a role in analyzing the data and had access to the
primary clinical trial data.
3 | RESULTS
3.1 | Patients and treatment
The full analysis set comprised 142 patients who received treatment
with copanlisib, of whom 141 had indolent lymphoma. Patient demo-
graphics and baseline characteristics are presented in Table 1. The
median age at baseline was 63 years (range 25-82) and 50.0% of
patients were male. Patients received a median of three prior lines of
therapy (range 2-9); all patients had received rituximab and alkylating
agents, with 80.3% of patients refractory to any prior therapy and
60.6% refractory to the last regimen. In total, 19 patients (13.4%)
received prior high-dose chemotherapy or autologous stem cell trans-
plant. No patients received allogeneic stem cell transplant prior to or
during the study, though eight patients (5.6%) received allogeneic
stem cell transplant during follow-up.
Detailed study results of the primary analysis have been reported
previously.2 At the time of the primary analysis, 46 patients were still
receiving treatment, whereas 11 (7.7%) remained on treatment at the
extended database cut-off. Overall, the reasons for discontinuation of
treatment were radiological progressive disease (31.7%; 45/142), AEs
not associated with disease progression (26.8%; 38/142), study with-
drawal by patient (14.1%; 20/142), AEs associated with clinical dis-
ease progression (10/142; 7.0%), clinical progressive disease (8/142;
5.6%), physician decision (5/142; 3.5%), sponsor decision, protocol
deviation, protocol violation, and death (1/142 each; 0.7%).
3.2 | Safety profile
The median duration of copanlisib treatment was 26 weeks (range
1-192). This corresponded to a median of 6.5 treatment cycles (range
0.3-48.0). Patients received a median of 95.1% of the planned dose
(range 51.0-102.8). In total, 70 patients (49.3%) received copanlisib
for up to 6 months, 35 patients (24.6%) received copanlisib for
between 6 months and 1 year, and 37 patients (26.1%) received
copanlisib for more than 1 year, including seven patients (4.9%) who
received treatment for more than 3 years. The median duration of
safety follow-up was 6.7 months (range 0.2-44.1).
Treatment-emergent AEs (TEAEs) of any grade were reported for
140/142 patients (98.6%), which remained unchanged with the longer
follow-up since the primary analysis. The most common TEAEs of any
grade were transient hyperglycemia (50.0%), diarrhea (35.2%), tran-
sient hypertension (29.6%), neutropenia (28.9%), pyrexia (26.8%), and
fatigue (26.1%) (Table 2). Newly occurring worst-grade events of any
grade did not increase more than 5% vs the primary analysis set.
Drug-related TEAEs were reported in 127/142 patients (89.4%), one
additional patient than reported at the primary analysis, and are pres-
ented in Supporting Information, Table S1.
Grade 3 TEAEs were experienced by 77 patients (54.2%) and
grade 4 events were experienced by 41 patients (28.9%), an addition
of two and three patients, respectively, compared with the primary
analysis (Table 2). The most common grade 3 TEAEs were
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hyperglycemia (33.1%) and hypertension (23.9%), and the most com-
mon grade 4 TEAEs were neutropenia (14.8%) and hyperglycemia
(7.0%). Overall, there were four additional cases of grade 3 diarrhea
(total 12 patients [8.5%]), two new cases of grade 3 bronchitis (total
2 patients [1.4%]), and two additional cases of grade 4 neutropenia
(total 21 patients [14.8%]) compared with the primary analysis. No
grade 4 diarrhea was reported. There were increased incidences of
one patient each for the following grade 3 TEAEs: hyperglycemia,
hypertension, neutropenia, pneumonia, and anemia. Of TEAEs of spe-
cial interest, one additional case of grade 3 pneumonitis was reported,
totaling two events (1.4%) overall (Table 2). Likewise, laboratory find-
ings of elevated liver enzymes (any grade) were less than 5% (Table 2).
Serious AEs (SAEs) were reported in 79 patients (55.6%), com-
pared with 71 patients (50.0%) at the time of the primary analysis.
The most common all-grade SAEs occurring in at least three patients
were pneumonia (16/142; 11.3%), pyrexia (9/142; 6.3%), hyperglyce-
mia (7/142; 4.9%), and pneumonitis (6/142; 4.2%) (Supporting Informa-
tion, Table S2). Of SAEs of grade ≥3, there was one new or additional
case each of the following grade 3 events: cholecystitis, pneumonitis,
Klebsiella bacteremia, afferent loop syndrome, disorientation, abdominal
pain, and pulmonary embolism; and one additional case each of the fol-
lowing grade 4 events: chronic lymphocytic leukemia and sepsis.
Overall, rates of pneumonitis (9/142 [6.3%], all grade) and colitis
(1/142 [0.7%], grade 4) remained low and were unchanged from the
primary analysis. The one grade 4 event of colitis occurred early in
treatment (day 28-34) in a patient with a history of diverticulosis; the
patient responded to antibiotics with no recurrence at a reduced dose.
No new treatment-emergent mortality was observed in the
extended analysis compared with the primary analysis; 6/142 patients
(4.2%) experienced grade 5 events during treatment or within 35 days
following permanent discontinuation, with three events (2.1%)
TABLE 1 Patient demographics and baseline characteristics
Total (N = 142)2
Males, n (%) 71 (50.0)
Median age, years (range) 63 (25–82)
Race, n (%)
White 120 (84.5)
Asian 15 (10.6)
Not reported 7 (4.9)
Histology of tumor, n (%)a
FL (grades 1-3a)b 104 (73.2)
MZL 23 (16.2)
SLL 8 (5.6)
WM/LPL 6 (4.2)
DLBCLc 1 (0.7)
Ann Arbor Conference
classification of disease
stages at study entry, n (%)
I 3 (2.1)
II 25 (17.6)
III 32 (22.5)
IV 82 (57.7)
Mean serum LDH at
baseline, units/L (SD)d
298.4 (185.9)
Baseline ECOG PS, n (%)
0 80 (56.3)
1 57 (40.1)
2 5 (3.5)
Median time from most
recent progression, weeks
(range)
8.3 (1–73)
Median number of prior anti-
cancer therapy lines
(range)
3 (2–9)
Prior therapy, n (%)
Rituximab 142 (100)
Alkylating agents 142 (100)
High-dose chemotherapy/
autologous stem cell
transplant
19 (13.4)
Refractory,e n (%) 114 (80.3)
Rituximab 100 (70.4)
Rituximab and any other
treatmentf
79 (55.6)
(Continues)
TABLE 1 (Continued)
Total (N = 142)2
Refractory to last regimen,
n (%)
86 (60.6)
Rituximab 80 (56.3)
Alkylating agentsg 61 (43.0)
Rituximab and alkylating
agentsg
61 (43.0)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; ECOS PS, Eastern
Cooperative Oncology Group performance status; FL, follicular lymphoma;
LDH, lactate dehydrogenase; MZL, marginal zone lymphoma; SD, standard
deviation; SLL, small lymphocytic lymphoma; WM/LPL, Waldenström
macroglobulinemia/lymphoplasmacytoid lymphoma.
aHistology was determined based on investigator assessment.
bGrade of FL was not available for three patients.
cThe patient with DLBCL was initially assessed by the investigator as
having indolent lymphoma, which was later confirmed by both the
investigator and central pathology review to be DLBCL; however, the
patient received treatment and was included in the full analysis set.
dn = 35.
eA patient was considered refractory to an anti-cancer therapy if they had
a best response of progressive disease, stable disease, or unknown for ≥1
anti-cancer regimen or if the response lasted <6 months.
fExcluding transplant/radiotherapy or non-conventional therapy.
gSince completion of the primary analysis, the WHO Drug Dictionary has
been updated to include cisplatin as an alkylating agent; therefore, one
additional patient who received cisplatin as the last regimen was
included in the alkylating agents group who did not qualify at the time of
the primary analysis.
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considered treatment related (lung infection, respiratory failure, and
embolism [0.7% each]).
Of the 142 patients who were treated with copanlisib, 38 patients
(26.8%) discontinued due to an AE not associated with disease pro-
gression, of which the majority (15%) occurred within the first
6 months of treatment and were highest in the first 3 cycles of treat-
ment. The most common TEAEs leading to permanent discontinuation
included pneumonitis in five patients (3.5%), neutropenia in four
patients (2.8%), and diarrhea, hyperglycemia, and thrombocytopenia
in three patients (2.1%) each. A total of 30 patients (21.1%) discon-
tinued due to an AE attributed to copanlisib.
The TEAEs leading to dose reductions were recorded in 40 patients
(28.2%), most commonly hyperglycemia (n = 12), neutropenia (n = 8),
hypertension (n = 6), and pneumonitis (n = 4). Dose reduction to 45 mg
occurred in 41 patients (28.9%) for a median of 6.0 weeks (range
0-64.0). Dose interruptions or delays were experienced by 116/142
patients (81.7%), an additional 11 patients since the primary analysis.
Thirty-four patients experienced one interruption or delay, 24 patients
experienced two interruptions or delays, and 20 patients experienced
three interruptions or delays; the remaining 38 patients experienced
four or more interruptions or delays. The median time of interruption
or delay was 1.0 week (range 0-2.9); 96.6% of interruptions/delays
lasted 1 week or less. The TEAEs leading to dose interruptions were
recorded in 97 patients (68.3%), most commonly neutropenia (n = 28),
hypertension (n = 11), pneumonia (n = 11), bronchitis (n = 10), diarrhea
(n = 8), and pyrexia (n = 7).
TABLE 2 Summary of TEAEs and incidence of most common TEAEs
June 2016 data cut-off (N = 142) February 2018 data cut-off (N = 142)
n (%) Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
TEAE 140 (98.6) 75 (52.8) 38 (26.8) 140 (98.6) 77 (54.2) 41 (28.9)
TEAEs occurring in ≥10% of the total population
Non-hematologic toxicities
Hyperglycemia 69 (48.6) 46 (32.4) 10 (7.0) 71 (50.0) 47 (33.1) 10 (7.0)
Diarrhea 48 (33.8) 8 (5.6) 0 50 (35.2) 12 (8.5) 0
Hypertension 42 (29.6) 33 (23.2) 0 42 (29.6) 34 (23.9) 0
Pyrexia 36 (25.4) 6 (4.2) 0 38 (26.8) 6 (4.2) 0
Fatigue 36 (25.4) 3 (2.1) 0 37 (26.1) 3 (2.1) 0
Nausea 33 (23.2) 1 (0.7) 0 33 (23.2) 1 (0.7) 0
Cough 24 (16.9) 0 0 27 (19.0) 0 0
Upper respiratory tract infection 19 (13.4) 2 (1.4) 0 21 (14.8) 2 (1.4) 0
Pneumonia 18 (12.7) 12 (8.5) 2 (1.4) 20 (14.1) 13 (9.2) 2 (1.4)
Vomiting 18 (12.7) 0 0 20 (14.1) 0 0
Constipation 17 (12.0) 0 0 18 (12.7) 0 0
Decreased appetite 15 (10.6) 0 0 15 (10.6) 0 0
Bronchitis 13 (9.2) 0 0 16 (11.3) 2 (1.4) 0
Back pain 12 (8.5) 0 0 15 (10.6) 1 (0.7) 0
Hematologic toxicities
Neutropenia 36 (25.4) 12 (8.5) 19 (13.4) 41 (28.9) 13 (9.2) 21 (14.8)
Anemia 20 (14.1) 6 (4.2) 0 25 (17.6) 7 (4.9) 0
Thrombocytopenia 19 (13.4) 7 (4.9) 0 20 (14.1) 7 (4.9) 0
TEAEs of special interest
Pneumonitisa 10 (7.0) 1 (0.7) 0 9 (6.3) 2 (1.4) 0
Colitis 1 (0.7) 0 1 (0.7) 1 (0.7) 0 1 (0.7)
Laboratory toxicities
ALT increasedb 4 (2.8) 1 (0.7) 0 6 (4.2) 1 (0.7) 0
AST increasedb 2 (1.4) 0 0 3 (2.1) 0 0
Note: AEs were classified by using the Medical Dictionary for Regulatory Activities (MedDRA; version 20.1) and graded by using the National Cancer
Institute Common Terminology Criteria for Adverse Events (version 4.03).
Abbreviations: AE, adverse event; ALT, alanine transaminase; AST, aspartate aminotransferase; TEAE, treatment-emergent adverse event.
aOne patient initially diagnosed with pneumonitis at the primary cut-off was later confirmed to have infection and the MedDRA entry was corrected
accordingly by the investigator, totaling nine patients with any-grade pneumonitis.
bMissing values for 1 patient.
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Because of reports of delayed or late-onset AEs associated with
continuously dosed oral PI3K inhibitors, in addition to the overall inci-
dence of AEs as commonly reported (Table 2), we further evaluated
the incidence and severity of AEs over the course of treatment. Spe-
cifically, we determined the incidence of new or worsening AEs within
specific time intervals: patients treated up to 6 months (n = 142),
between 6 and 12 months (n = 72), and >12 months (n = 37).
The assumption was that if there were cumulative toxicity or late-
onset AEs, then AEs would occur at a higher incidence or higher grade
following longer treatment. As shown in Figure 1A for AEs with over-
all incidence of ≥25% and in Supporting Information, Table S3 for all
AEs >10%, the highest incidence of AEs was seen early in the
<6-months interval, with reduction in incidence and grade in the
6-12 months and >12-months intervals. The possible exception was
grade 3 diarrhea, which was reported in 10.8% of patients treated for
>12 months compared with 4.9% of patients treated for <6 months
(it should be noted, however, that the treatment interval in the
>12-month group was as long as 192 weeks compared to the earlier
6-month intervals). There were no reports of grade 4 diarrhea and
only one case of colitis in this study (grade 4, <6-month interval).
For the 37 patients who received copanlisib for more than 1 year,
there was no evidence for higher incidences of new or worsening
(A)
(B)
F IGURE 1 Time of onset for the most common TEAEs for A, all patients (total, N = 142; <6 months, n = 142; 6-12 months, n = 72;
>12 months, n = 37); and B, patients treated for >12 months (n = 37). The >12-month category includes patients with up to 44.3 months
(192 weeks) of treatment. TEAE, treatment-emergent adverse event
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TEAEs occurring after 12 months of treatment compared with those
occurring in the first 6 months of treatment in the same group of
patients (Figure 1B and Supporting Information, Table S4). The inci-
dences of worst grade 3 and grade 4 hyperglycemia and hypertension
were lower in the 6-12 months and >12-months intervals for patients
treated for more than 1 year compared with the incidences occurring
during <6 months of treatment. Grade 3 hyperglycemia was reported
in 11/37 patients (29.7%) in the first 6 months of treatment and in
3/37 patients (8.1%) after 1 year; grade 4 hyperglycemia was reported
in two patients (5.4%) in the first 6 months and one patient (2.7%)
after 1 year of treatment. Grade 3 hypertension was experienced by
10/37 patients (27.0%) in the first 6 months of treatment and by 6/37
patients (16.2%) after 1 year; none of the 37 patients had grade
4 hypertension. There was one additional worst grade 3 diarrhea event
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at the later time interval; 3/37 patients (8.1%) in the first 6 months and
4/37 patients (10.8%) after 1 year of treatment. There was no grade
4 diarrhea reported in any interval. Similarly, elevations in liver enzymes
were not seen (Supporting Information, Table S4). For the patients
receiving treatment for more than 1 year, no grade 3 or grade 4 upper
respiratory tract infection occurred after 6 months of treatment, and
no grade 3 or grade 4 fatigue was reported at any time. Grade 3 pneu-
monitis was reported in 1/37 patients (2.7%; occurring after 1 year of
treatment), and no cases of colitis were reported at any time interval
for the patients treated in excess of 1 year. No fatal AEs were reported
in patients who received copanlisib for more than 1 year.
3.3 | Efficacy
Per independent central review, 24 patients (16.9%) achieved complete
response and 62 patients (43.7%) achieved partial response, resulting in
an ORR of 60.6% (86/142) (Supporting Information, Table S5), compared
with 17 patients with complete responses and an ORR of 59.2%
(84/142) at the time of the primary analysis. Stable disease was observed
in 41 patients (28.9%) and progressive disease occurred in three patients
(2.1%). Complete responses were observed in 21 patients with FL (com-
plete response rate of 20.2%; 21/104) and partial responses were
observed in 40 patients (38.5%; 40/104), resulting in an ORR of 58.7%
(61/104). In the subset of patients with MZL, three patients achieved a
complete response (complete response rate of 13.0%; 3/23) and
15 patients achieved a partial response (65.2%; 15/23), resulting in an
ORR of 78.3% (18/23). The seven additional complete responses were
observed in six patients with FL and one patient with MZL. One addi-
tional partial response was observed in a patient with MZL who had sta-
ble disease at the primary analysis. The overall disease control rate
remained unchanged at 85.9% (122/142).
Response rates were consistent across subgroups (Supporting
Information, Figure S1), including by patient age, tumor size, the num-
ber of prior lines of therapy, and whether patients were refractory to
their last therapy. Median time to response was 1.8 months (range
1.3-17.3). Median time to complete response was 4.7 months (range
1.5-20.9).
Of those evaluated for lesion size, 116/126 patients (92.1%)
experienced a reduction in target lesion size from baseline following
treatment with copanlisib (Figure 2A). A reduction of at least 50% was
experienced by 79/126 patients (62.7%), compared with 74/125
patients (59.2%) at the time of the primary analysis.
Median DoR was 14.1 months (range 0.03-42.5), with a median
follow-up of 16.1 months; median duration of complete response was
26.0 months (range 1.9-34.5) (Figure 2B). There were 72 progressions,
and median PFS was 12.5 months (range 0.03-44.2) (Figure 2C), with
a median follow-up of 14.0 months; the PFS rate at 2 years was 34%.
Fifty-two patients died, and median OS was 42.6 months (range
0.2-49.9) (Figure 2D), with a median follow-up of 31.5 months; the
OS rate at 2 years was 69%. Although patients with WM/LPL had the
lowest ORR (16.7%) of any subset, tumor shrinkage was seen in all
patients with measurable disease (Figure 2A).
For the 41 patients (28.9%) who had stable disease as best response,
the median duration of stable disease was 7.2 months (range 1.3-23.0).
4 | DISCUSSION
Long-term follow-up data from the large multicenter CHRONOS-1
study of copanlisib demonstrated continued safety and enhanced effi-
cacy in patients with relapsed or refractory indolent B-cell lymphoma.
In the 2-year follow-up of the primary analysis, an overall ORR of
60.6% was achieved, compared with 59.2% at the time of the primary
analysis,2 and indicated some deepening of responses with time on
treatment, principally partial response to complete response. Six
patients who initially had a partial response at the primary analysis
achieved complete response at the later cut-off, and one patient who
initially had stable disease achieved a partial response at the later cut-
off. Indeed, the median time to complete response (4.7 months) was
more than twice the median time to first response (1.8 months). The
ORR in patients with FL remained at 58.7%, while the ORR in patients
with MZL increased to 78.3%. The proportion of patients with a pri-
mary response of progressive disease was low (2.1%). The ORR was
consistent across the various subgroups, including patients aged
<65 years or ≥65 years and patients who were or were not refractory
to last treatment.
The median DoR overall was 14.1 months and was greater than
2 years for patients with complete responses. Median PFS was
greater than 1 year. Median OS was demonstrated to be more than
3.5 years with copanlisib treatment.
These efficacy data for copanlisib suggest favorable response rates,
generally consistent with or better than those reported for other PI3K
inhibitors to date. A 20-month follow-up of the oral PI3K-δ inhibitor
idelalisib reported an ORR of 56% in refractory indolent B-cell lym-
phoma19 (ORR of 57% at the primary evaluation).5 The median DoR
(13.9 months) and median PFS (11.0 months)19 were similar to those
observed with copanlisib. The PI3K-δ and -γ inhibitor duvelisib achieved
an ORR of 47.3% and median PFS of 9.5 months in patients with indo-
lent refractory lymphoma.6 The PI3K-δ inhibitor umbralisib demonstrated
an ORR of 36.7% in patients with hematological malignancies,20 while an
ORR of 25% was reported in a phase 2 study of the oral pan-PI3K inhibi-
tor buparlisib (median PFS of 9.8 months in patients with FL).21
Overall, the most common TEAEs of any grade reported with
long-term treatment with copanlisib were transient hyperglycemia
(50.0%), diarrhea (35.2%), transient hypertension (29.6%), neutropenia
(28.9%), and pyrexia (26.8%), remaining consistent with the primary
analysis and with previous reports of copanlisib.2,22,23 Events contin-
ued to be transient and manageable. Hyperglycemia has also been
reported as a common TEAE with other PI3K inhibitors21,24-26 and is
believed to be an on-target effect of PI3K-α inhibition due to its well-
described role in insulin signaling.27 The incidence and severity of
hyperglycemia with copanlisib were similar to those reported with the
orally administered α-selective PI3K inhibitor alpelisib.28 Although
hyperglycemia with the latter agent is presumably more prolonged
due to daily administration, hyperglycemia observed with copanlisib
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administered intravenously once weekly is transient and returns to
baseline within 24 hours.29 Interestingly, the incidences of hypergly-
cemia and hypertension appeared to decrease in later use compared
with the earlier time points. Whether this reflects improved patient
management or the development of tolerance cannot be determined
at this time. In general, in later treatment intervals and for the patients
treated for more than 1 year with copanlisib, the most commonly
reported events showed no evidence for increased incidence or wors-
ening severity following longer exposure, suggesting that worst-grade
TEAEs tended to occur earlier in treatment. In addition, there was no
evidence of new or unexpected TEAEs in patients exposed to
copanlisib for longer duration. The safety profile that was observed
from this extended analysis remains consistent with the known safety
profile of copanlisib.
Of particular interest was whether there was an occurrence of late-
onset worst-grade or severe toxicities with longer exposure to
copanlisib. An additional four patients experienced grade 3 diarrhea
(total incidence of grade 3 diarrhea was 8.5%). In the 37 patients treated
with copanlisib for more than 1 year, four patients experienced grade
3 diarrhea with an onset after 12 months of treatment, although it
is important to note that some patients in this subgroup had received
treatment for more than 3 years. Overall, there were no cases of grade
4 diarrhea. Rates of individual severe toxicities also remained low, with
all-grade SAEs of pneumonitis (4.2%), hyperglycemia (4.9%), and diarrhea
(2.8%) unchanged at the extended cut-off date; there was one additional
patient with all-grade SAE of lung infection. Colitis (one case overall) or
other severe gastrointestinal toxicities or hepatic transaminase eleva-
tions remained low, suggesting a lack of late-onset toxicities of concern
for patients receiving extended treatment with copanlisib. Higher rates
of diarrhea and other severe gastrointestinal toxicities have been
reported with other PI3K inhibitors that are approved for the treatment
of B-cell lymphoma. This includes a phase 2 study of duvelisib with a
similar median duration of treatment (6.7 months)6 as well as a phase
2 study of idelalisib with a longer median duration of treatment
(11.1 months).19 In addition, higher rates of colitis, ulcerative colitis, and
other severe gastrointestinal toxicities have been reported for idelalisib9
and for duvelisib.6 The low rate of severe gastrointestinal toxicities such
as colitis or severe liver enzyme elevations reported with copanlisib
may be attributable to lower exposure of the gastrointestinal tract to
copanlisib due to the intermittent dose schedule and intravenous route
of administration vs continuously administered oral agents such as
idelalisib9 or duvelisib.30
In conclusion, long-term follow-up of copanlisib demonstrated
sustained and enhanced efficacy over time, including additional durable
complete responses. The AEs remained transient and manageable over
time, including in those patients treated with copanlisib for more than
1 year. No new or unexpected TEAEs were reported in patients exposed
to copanlisib for longer duration. In addition, the lack of late-onset toxic-
ities and severe gastrointestinal toxicities suggests that the approved
intravenous route of administration and the intermittent dose schedule
for copanlisib benefit tolerability. Studies are currently investigating
copanlisib in combination with standard of care treatments in relapsed
indolent non-Hodgkin lymphoma (NCT02367040 andNCT02626455).
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